Please login to the form below

Not currently logged in
Email:
Password:

Ocaliva

This page shows the latest Ocaliva news and features for those working in and with pharma, biotech and healthcare.

Roche enters NASH race with deal to buy Jecure

Roche enters NASH race with deal to buy Jecure

Among these, Intercept’s Ocaliva (obeticholic acid) is already approved to treat rare liver disease primary biliary cirrhosis, and is in phase 3 for NASH patients with cirrhosis, while Gilead Sciences

Latest news

More from news
Approximately 6 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics